Calusterone

Area of Science:

• Oncology
• Endocrinology

Background:

• Androgens are established therapeutic agents for postmenopausal women with metastatic breast cancer.
• Early studies demonstrated objective regression rates exceeding 20% with testosterone propionate.
• Subsequent synthetic androgens have not improved upon testosterone propionate's efficacy or toxicity profile.

Purpose of the Study:

• To evaluate the efficacy and toxicity of calusterone (7 beta,17 alpha-dimethyltestosterone) as a potential therapeutic agent for metastatic breast cancer.
• To compare calusterone's therapeutic profile against existing androgen therapies, including testosterone propionate.

Main Methods:

• Review of early and subsequent clinical trial data for calusterone.
• Comparative analysis of efficacy (objective regression rates) and toxicity data for calusterone versus other androgens.
• Assessment of the consistency and reliability of available clinical data on calusterone.

Main Results:

• Early clinical trials suggested calusterone possessed superior efficacy and reduced toxicity compared to testosterone propionate.
• Later studies failed to consistently confirm these initial promising findings.
• Data on calusterone's performance in breast cancer treatment remain largely inconsistent.

Conclusions:

• Current evidence indicates that calusterone does not offer significant therapeutic advantages over other androgens for treating breast cancer.
• The initial perception of calusterone as an "ideal androgen" was not substantiated by subsequent research.
• Further investigation may be needed to clarify calusterone's role, if any, in breast cancer therapy.